)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ZyVersa Therapeutics
ZyVersa Therapeutics (ZVSA) investor relations material
ZyVersa Therapeutics has been otc
ZyVersa Therapeutics Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary13 May, 2026
Executive summary
Clinical-stage biopharma advancing a pipeline for renal and inflammatory diseases, with lead candidates VAR 200 and IC 100 targeting FSGS, Alport Syndrome, and cardiometabolic conditions.
Total accessible market for lead assets exceeds $100 billion.
No revenue generated to date; operations funded by equity and debt issuances.
Net loss for Q1 2026 was $1.8 million, improved from $2.3 million in Q1 2025.
Accumulated deficit reached $139.4 million as of March 31, 2026.
Financial highlights
Research and development expenses decreased 77.6% year-over-year to $58,000, mainly due to lower payroll and paused studies.
General and administrative expenses fell 33.9% to $1.2 million, driven by reduced professional, marketing, and tax costs.
Net loss per share improved to $(0.22) from $(0.73) year-over-year.
Net cash used in operating activities was $0.8 million, down from $1.8 million in Q1 2025.
$1.0 million raised via convertible notes and warrants in Q1 2026.
Outlook and guidance
Cash balance of $0.3 million as of March 31, 2026, only sufficient for month-to-month operations; significant additional losses expected for several years.
Ongoing need for additional capital to fund operations and product development, with plans to raise funds through equity, debt, grants, collaborations, or warrant exercises.
IND filing for IC 100 expected in Q4 2026, with Phase 1 readout in H1 2027; Phase 2a trial for VAR 200 to start H2 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ZyVersa Therapeutics
- Net loss surged on R&D impairment; pipeline milestones and new funding are critical in 2026.ZVSA
Q4 2025 - Biopharma seeks up to $100M via flexible securities shelf amid pipeline progress and going concern risk.ZVSARegistration Filing
- Biopharma registers 1.6M shares for resale; faces major funding needs and going concern risk.ZVSARegistration Filing
- Registering 478,600 shares for resale, company faces urgent funding needs and going concern risks.ZVSARegistration Filing
- Registering 4.2M shares for resale tied to warrants, with major funding needs and early-stage pipeline.ZVSARegistration Filing
- Annual meeting covers director election, auditor, equity plan, and warrant-related stock issuance.ZVSAProxy Filing
- Shareholders will vote on director elections, auditor ratification, equity plan, and major warrant issuances.ZVSAProxy Filing
- IC100 and VAR-200 advance toward key clinical milestones, targeting obesity and kidney disease.ZVSALife Sciences Investor Forum
- All four shareholder proposals were approved, with board and management updates provided.ZVSAAGM 2024
ZyVersa Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company dedicated to developing innovative drugs for renal and inflammatory diseases with significant unmet medical needs. The company leverages advanced proprietary technologies to create first-in-class therapeutics. Its key product candidates include the Cholesterol Efflux Mediator VAR 200, which is being developed to remove excess cholesterol from the kidneys' filtration system to prevent damage and reduce proteinuria, potentially treating conditions like diabetic kidney disease, focal segmental glomerulosclerosis (FSGS), and Alport syndrome. Another major candidate is the Inflammasome ASC Inhibitor IC 100, a monoclonal antibody designed to inhibit inflammation by targeting the ASC protein, which is implicated in a variety of inflammatory conditions, including neuroinflammatory diseases like Parkinson’s and Alzheimer’s, as well as metabolic complications related to obesity. The company is headquartered in Weston, Florida, and its shares are listed on the NASDAQ.